Oral-steroid sparing effect of inhaled fluticasone propionate in children with steroid-dependent asthma

BackgroundThere is scarcity of data on impact of rituximab on anthropometrical parameters (weight, height and body mass index i.e. BMI SD score (SDS)) among children with steroid-dependent nephrotic syndromes (SDNS).MethodsMulticentre retrospective review.Results102 children with SDNS (male: 63%; n=64), median age 7 (IQR: 4.3–9.6) years, received a total of 217 rituximab infusions (total 110 cycles). At median follow-up of 2.1 (IQR: 1.3–2.8) years, 58 (57%) children were off steroids and a significant fall in steroid threshold for relapse was noted (median 0.6; IQR 0.4–0.9 to median 0.3; IQR 0.12 - 0.5 mg/kg/alternate day, p=0.005). Anthropometric parameters (BMI SDS: 0.92±1.8 to 0.25±1.47, p=0.003; weight SDS: 0.20±1.6 to −0.11±1.3, p=0.01; and height SDS: −0.93±1.88 to −0.45±1.54, p=0.04) as well as obesity (38% to 20%, p=0.003) and short stature (11% to 3%, p=0.02) improved. Results remained significant even when analysis was restricted to children ≤12 years (n=88), (BMI SDS: 0.97±1.98 to 0.25±1.5, p=0.001; weight SDS: 0.33±1.6 to 0.02±1.2, p=0.01; and height SDS: −0.67±1.84 to −0.186±1.42, p=0.001).ConclusionsUse of rituximab resulted in significant steroid sparing effect with an improvement in both growth and obesity parameters.

Download Full-text

P588 Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.709 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S539-S539

Author(s):

M Sina ◽

E Pengili ◽

X Pemaj ◽

D Osmanaj ◽

I Bibolli ◽

...

Keyword(s):

Ulcerative Colitis ◽

Clinical Remission ◽

Tertiary Hospital ◽

Average Dose ◽

Biologic Treatment ◽

Steroid Dose ◽

Steroid Dependent ◽

Sparing Effect ◽

Steroid Sparing

Abstract Background Corticosteroids are indicated for induction of remission in moderate to severe ulcerative colitis (UC) patients. However, due to their adverse effects associated with long-term use, steroids are not indicated as a maintenance therapy. The aim of this study was to assess the steroid sparing effect of adalimumab (ADA) in steroid-dependent UC patients. Methods This is a prospective study carried out at a tertiary hospital center in Albania from 2016–2020, including consecutive moderate-to-severe UC patients. All patients received biologic therapy with subcutaneous ADA 160/80mg at weeks 0/2 followed by 40mg every 2 weeks. We evaluated the steroid-sparing effect of ADA measuring the number of steroid–free patients and the average steroid dose at baseline before initiating biologic treatment and at week 8, 24, 52, 104, 156. Clinical remission was defined as total Mayo score ≤ 2 points. Results We enrolled 26 UC patients, mean age 47.3 ± 16.1 (24–85) years, 55.6% were females. The average disease duration before starting ADA was 7.3 ± 7.0 years (range 1–33); 44.4% had pancolitis and 55.6% left side colitis. 8(29.6%) patients were on combination therapy with azathioprine. 17/26 (65.4%) patients were taking prednisone at the time of the first ADA injection with an average dose of 17.7mg. The number of steroid-free patients at week 8, 24, 52, 104 and 156 was 12/26 (46.2%), 16/26 (61.5%), 15/21 (71.4%), 11/14 (78.6%), 8/9 (88.9%) respectively. At the end of the follow-up (week 156), the proportion of steroid free patient was significantly higher than at baseline [88.9% (8/9) vs 34.6% (7/26), p=0.005]. The reduction of the average dose of prednisone (8.8 mg, 4 mg, 6.8mg, 3.8mg and 3,8mg at week 8, 24, 52, 104 and 156 respectively), was also statistically significant (p<0.01). Clinical remission rates were 7.7% (2/26) at week 8, 47.6% (10/21) at week 52, 42.9% (6/14) at week 104 and 44.4 % (4/9) at week 156. Conclusion In our cohort, ADA administration to moderate–to severe UC significantly reduced the steroid dose and the proportion of patients taking cortisone during 3 years follow-up.

Download Full-text

A double‐blind, placebo‐controlled steroid‐sparing study with budesonide Turbuhaler in Japanese oral steroid‐dependent asthma patients

Respirology ◽

10.1046/j.1440-1843.2000.00254.x ◽

2000 ◽

Vol 5 (3) ◽

pp. 231-240 ◽

Cited By ~ 11

Author(s):

Terumasa Miyamoto ◽

Terumi Takahashi ◽

Shigenori Nakajima ◽

Sohei Makino ◽

Michio Yamakido ◽

...

Keyword(s):

Oral Steroid ◽

Double Blind ◽

Double Blind Placebo ◽

Steroid Dependent ◽

Asthma Patients ◽

Steroid Sparing

Download Full-text

Steroid sparing effect of a herbal preparation in steroid-dependent nephrotic syndrome

Pediatric Nephrology ◽

10.1007/s00467-006-0054-1 ◽

2006 ◽

Vol 21 (7) ◽

pp. 1031-1033 ◽

Cited By ~ 2

Author(s):

Arpana Iyengar ◽

Hrishikesh Damle ◽

Chanda Kulkarni ◽

Latha Damle ◽

Kishore Phadke

Keyword(s):

Nephrotic Syndrome ◽

Herbal Preparation ◽

Steroid Dependent ◽

Sparing Effect ◽

Steroid Sparing ◽

Steroid Dependent Nephrotic Syndrome

Download Full-text

A steroid sparing effect of ketotifen in steroid-dependent asthmatics

Clinical & Experimental Allergy ◽

10.1111/j.1365-2222.1980.tb02132.x ◽

1980 ◽

Vol 10 (5) ◽

pp. 519-525 ◽

Cited By ~ 32

Author(s):

D. J. LANE

Keyword(s):

Steroid Dependent ◽

Sparing Effect ◽

Steroid Sparing

Download Full-text

Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children

Journal of Ophthalmic and Vision Research ◽

10.18502/jovr.v14i4.5439 ◽

2019 ◽

Cited By ~ 1

Author(s):

Arkendu Chatterjee ◽

Sabyasachi Bandyopadhyay ◽

Samir Kumar Bandyopadhyay

Keyword(s):

Placebo Group ◽

Side Effects ◽

Cyclosporine A ◽

Controlled Study ◽

Vernal Keratoconjunctivitis ◽

Indian Children ◽

Steroid Dependent ◽

Sparing Effect ◽

Steroid Sparing

Purpose: To evaluate the efficacy, safety, and steroid-sparing effect of topical cyclosporine A (Cs A) 0.05% in patients with moderate to severe steroid dependent vernal keratoconjunctivitis (VKC). Methods: A prospective, comparative, placebo controlled study was carried out on 68 VKC patients, with 34 patients treated with topical Cs A 0.05% and the remaining 34 with topical carboxymethyl cellulose 0.5% (placebo). Both groups also received topical loteprednol etabonate 0.5%. Symptom (itching, photophobia, tearing, and discharge) score, sign (tarsal and limbal papillae, corneal involvement, and conjunctival hyperemia) score, and drug score (steroid drop usage/day/eye) were recorded at baseline and each followup visit. The intraocular pressure (IOP) measurement and evaluation of any ocular side effects were carried out. Results: Significant reduction in symptom score and sign score was seen in both groups. Cs A group significantly showed more reduction in symptom (P < 0.0001 in all follow-up visits) and sign (P < 0.0001 in all follow-up visits) scores compared to the placebo group. At day 7, mean steroid usage reduced from 4 to 3.44 ± 0.5 and 3.79 ± 0.4 in Cs A and placebo groups, respectively (P < 0.0001). Steroid drops completely stopped in 21 patients at day 60 in the Cs A group compared to none in the placebo group. No significant rise in IOP or any side effects were noted in either group. Conclusion: Topical Cs A 0.05% is effective and safe in patients with moderate to severe VKC with good steroid-sparing effect.

Download Full-text

Achieving control of steroid-dependent asthma with fluticasone propionate or salmeterol / fluticasone propionate: result of the Russian multicentre study GROZA

Russian Pulmonology ◽

10.18093/0869-0189-2005-0-5-87-92 ◽

2005 ◽

pp. 87-92

Author(s):

R. S. Fassakhov ◽

I. D. Reshetnikova ◽

N. I. Ilyina ◽

F. I. Petrovsky ◽

L. M. Ogorodova ◽

...

Keyword(s):

Quality Of Life ◽

Fluticasone Propionate ◽

Multicentre Study ◽

Asthma Control ◽

Oral Steroid ◽

Efficacy And Safety ◽

Steroid Dependent ◽

Asthma Patients ◽

Oral Steroids

The aim of the study was to assess efficacy and safety of 24-month treatment with Seretide (salmeterol / fluticasone propionate, 100 / 1 000 mcg daily) or Flixotide (fluticasone propionate, 1 000 mcg daily) in 105 steroid-dependent asthma patients aged 18 to 60 yrs who had received oral steroids for at least 6 months but not longer than 10 years. Methods. The study was comparative, randomized, multicentre, open in parallel groups (15 visits with 2-week intervals). Reduction of oral steroid doses started at the 3-rd visit. Results. In spite of the continual treatment with oral steroids patients did not reach asthma control. After 6-month therapy with fluticasone propionate or salmeterol / fluticasone propionate the maintaining dose of prednisolone was 6 times lower in comparison with baseline. Moreover, oral steroids were abolished in each second patient receiving Seretide and each third patient receiving Flixotide. The asthma control and quality of life significantly increased. Conclusion. The therapy with fluticasone propionate or salmeterol / fluticasone propionate allows to reduce doses of oral steroids and to cease oral steroids in most causes. Moreover, the patients can maintain good asthma control.

Download Full-text